155976-53-7

Basic information

• Product Name: 17(R)-HDOHE
• Synonyms: 17(R)-HDOHE;17R-HYDROXY-4Z,7Z,10Z,13Z,15E,17R,19Z-DOCOSAHEXAENOIC ACID;17(R)-HYDROXY DOCOSAHEXAENOIC ACID;SWTYBBUBEPPYCX-NGHKTGSUSA-N;17(R)-HDHA
• CAS NO: 155976-53-7
• Molecular Formula: C22H32O3
• Molecular Weight: 344.49
• Mol File: 155976-53-7.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 17(R)-HDOHE(CAS DataBase Reference)
• NIST Chemistry Reference: 17(R)-HDOHE(155976-53-7)
• EPA Substance Registry System: 17(R)-HDOHE(155976-53-7)

Safety Data

• Hazardous Substances Data: 155976-53-7(Hazardous Substances Data)

Usage

Description

17(R)-HDOHE, also known as 17(R)-Hydroxydocosahexaenoic acid, is a polyhydroxylated metabolite of docosahexaenoic acid (DHA) that is primarily produced when DHA is exposed to aspirin-inhibited cyclooxygenase-2. It serves as a precursor to resolvins and possesses intrinsic biological activity, such as inhibiting TNFα-induced IL-1β expression in human glioma cells.

Uses

Used in Pharmaceutical Applications:
17(R)-HDOHE is used as a bioactive compound for its anti-inflammatory and immunomodulatory properties. It plays a crucial role in the resolution of inflammation and has potential therapeutic applications in various inflammatory diseases and conditions.
Used in Research and Development:
In the field of biomedical research, 17(R)-HDOHE is used as a key intermediate in the synthesis of resolvins and other specialized pro-resolving mediators (SPMs). These compounds are being investigated for their potential roles in promoting tissue repair and resolving inflammation, which could lead to the development of novel therapeutic strategies for various diseases.
Used in Nutritional Supplements:
As a metabolite of DHA, 17(R)-HDOHE may also be used in the development of nutritional supplements that target inflammation and immune function. These supplements could potentially provide health benefits related to reducing inflammation and supporting overall immune system health.
Used in Drug Delivery Systems:
Similar to gallotannin, 17(R)-HDOHE could be incorporated into drug delivery systems to enhance its bioavailability and therapeutic outcomes. By using carriers such as organic or metallic nanoparticles, the delivery, efficacy, and targeting of 17(R)-HDOHE to specific cells or tissues could be improved, potentially leading to more effective treatments for various conditions.